Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows:
- royalties (58.8%);
- income from research and development (34.8%);
- other (6.4%): primarily income from partnership agreement.
At the end of 2019, the group had a portfolio of 18 products in clinical development phase and 20 in preclinical development phase.